Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.33 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1883048 | 0.85 | TAAR1 (0.40) | CHRNA7CHRNA10CHRNA9GRIN1GRIN2A | |
| Bromide SCHEMBL1893830 | 0.82 | L3MBTL1 (0.40) | — | |
| Bromide SCHEMBL1876920 | 0.81 | TAAR1 (0.44) | — | |
| SCHEMBL5297631 | 0.76 | SIGMAR1 (0.39) | CHRNA7CHRNA10CHRNA9 | |
| Hydrochloric Acid SCHEMBL20923487 | 0.74 | SIGMAR1 (0.38) | CHRNA7CHRNA10CHRNA9 | |
| Bromide SCHEMBL1894117 | 0.74 | SLC16A3 (0.37) | — | |
| Bromide SCHEMBL3469640 | 0.73 | KMT2A (0.42) | — | |
| Bromide SCHEMBL1883010 | 0.72 | CHRNA7 (0.46) | CHRNA7CHRNA10CHRNA9 | |
| Bromide SCHEMBL14896254 | 0.71 | KMT2A (0.50) | — | |
| SCHEMBL319304 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260397-B2 | Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2016-02-16 | — | — | US | disclosed |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | RDX, HAX1, CHRM2 | CHRNA7 264/4885CHRNA10 418/4885CHRNA9 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.